Auven Therapeutics has invested in therapeutic platform companies as well as individual therapeutic assets. The investments are managed or overseen by Auven Therapeutics Development team.
Auven Therapeutics has built a diversified portfolio of biologic and small molecule therapeutic candidates for a wide range of therapeutic indications. Its pipeline addresses critical unmet medical needs with large market potential in a multitude of cancers, different eye diseases and orphan diseases.
The Auven Therapeutics’ managed asset portfolio comprises:
Companies we are invested in include:
Auven Therapeutics invested in ADC Therapeutics Sarl in 2012. It is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based toxins.
As the Company’s PBD-based toxins or “warheads” do not distort the structure of the target cell’s DNA, its ADCs offer the prospect of highly potent, target-selective cancer therapies with fewer side effects and the potential to pre-empt resistance issues faced by other anti-cancer products on the market. The Company has an exclusive license from Spirogen, a subsidiary of MedImmune, the global biologics research and development arm of AstraZeneca, for its PBD chemistry platform for use in the Company’s proprietary programs.
In October 2013, ADC Therapeutics and MedImmune entered into a collaboration agreement for two of ADC Therapeutics’ oncology programs. MedImmune also invested $20 million in ADC Therapeutics alongside a $20 million additional investment from Auven Therapeutics. As part of the transaction, MedImmune’s Executive Vice President, Dr. Bahija Jallal, joined ADC Therapeutics’ board.
Details of the current ADCT trial can be found at: NCT02432235. Initial clinical trial sites for ADCT's product targeting lymphomas have opened at MD Anderson Cancer Center and the University of Texas Cancer Center. Patients are currently being recruited for enrollment.
Auven recently played a leading role in ADCT's $80 million private equity placement. Auven and existing investor AstraZeneca participated in the placement alongside a top-tier group of new European and US-based investors. For further information, please see the Press Release
ADC Therapeutics operates a virtual business model based in Lausanne, Switzerland.
For further information please visit their website.
In October 2013, Auven Therapeutics sold its portfolio company, Spirogen, to MedImmune, the global biologics research and development arm of AstraZeneca.
For further information about MedImmune’s acquisition of Spirogen, please see the press release here or visit Spirogen's website .
Auven Therapeutics’ original investment in Spirogen took place in 2009. Spirogen was a platform technology business specializing in novel, sequence-selective, DNA minor groove-binding molecules with potent therapeutic properties. The Company’s principal technology involved modification of members of a group of naturally occurring antibiotics called pyrrolobenzodiazepines (PBDs).
Auven Therapeutics invested in Kolltan Pharmaceuticals, Inc, in 2009. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is advancing a new generation of therapeutics in oncology and other diseases, based on seminal discoveries made in the laboratory of Dr. Joseph Schlessinger. Kolltan’s primary focus is to create novel biologic agents that can modulate the function of receptor tyrosine kinases (RTKs). Kolltan has approximately 30 employees, and since its inception in 2008, the Company has raised $75 million in equity funding. For more information please visit their website.
Auven Therapeutics invested in Sprout Pharmaceuticals, Inc., a spin-off of Slate Pharmaceuticals, Inc., in March 2012. In August 2015, Valeant Pharmaceuticals entered into an agreement to purchase Sprout along with the worldwide rights to Flibanserin for $1 billion in upfront consideration plus substantial sales milestone and royalty payments. Flibanserin is an FDA-approved centrally acting product showing promise in the treatment of selected aspects of female sexual dysfunction. For more information please visit their website.